î
îž
āļĨāđāļāļāļāļīāļ
î
Organon & Co
OGN6.100USD
-0.010-0.16%
āļāļīāļÂ 03/25, 16:00ïžETïžāļĢāļēāļāļēāļĨāđāļēāļāđāļē 15 āļāļēāļāļĩ
1.54BāļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
8.46P/E TTM
î
āļĢāļēāļĒāļĨāļ°āđāļāļĩāļĒāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļāļ Organon & Co āļāļĢāļīāļĐāļąāļ
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
āļāđāļāļĄāļđāļĨ Organon & Co
îāļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļOGN
āļāļ·āđāļāļāļĢāļīāļĐāļąāļOrganon & Co
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 14, 2021
āļāļĩāļāļĩāđāļMorrissey (Joseph T)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ10000
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļMay 14
āļāļĩāđāļāļĒāļđāđ30 Hudson Street
āđāļĄāļ·āļāļJERSEY CITY
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX NASDAQ Basic NYSE
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ07302
āđāļāļĢāļĻāļąāļāļāđ15514306000
āđāļ§āđāļāđāļāļāđhttps://www.organon.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļOGN
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 14, 2021
āļāļĩāļāļĩāđāļMorrissey (Joseph T)
āļāļđāđāļāļĢāļīāļŦāļēāļĢāļāļĢāļīāļĐāļąāļāļāļāļ Organon & Co
îāļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
180.10K
+19.78%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
90.89K
+20.91%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
79.44K
+24.57%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
72.38K
+26.99%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
54.43K
+24.06%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
2.00
--
Mr. Robert A. (Bob) Essner
Mr. Robert A. (Bob) Essner
Lead Independent Director
Lead Independent Director
--
--
Ms. Cynthia M. Patton
Ms. Cynthia M. Patton
Independent Director
Independent Director
--
--
Ms. Grace M. Puma Whiteford
Ms. Grace M. Puma Whiteford
Independent Director
Independent Director
--
--
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
180.10K
+19.78%
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
90.89K
+20.91%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
79.44K
+24.57%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
72.38K
+26.99%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
54.43K
+24.06%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
āļŠāļąāļāļŠāđāļ§āļāļāļāļāļĢāļēāļĒāđāļāđ
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 6 āļĄ.āļ.
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 6 āļĄ.āļ.
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Womenâs Health
429.00M
26.78%
Cardiovascular
307.00M
19.16%
Non-Opioid Pain, Bone and Dermatology
266.00M
16.60%
Other
220.00M
13.73%
Biosimilars
196.00M
12.23%
Respiratory
184.00M
11.49%
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Europe and Canada
417.00M
26.03%
United States
406.00M
25.34%
Latin America, Middle East, Russia and Africa
286.00M
17.85%
Asia Pacific and Japan
251.00M
15.67%
China
219.00M
13.67%
Other
23.00M
1.44%
āļāļēāļĄāļāļļāļĢāļāļīāļ
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļ
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Womenâs Health
429.00M
26.78%
Cardiovascular
307.00M
19.16%
Non-Opioid Pain, Bone and Dermatology
266.00M
16.60%
Other
220.00M
13.73%
Biosimilars
196.00M
12.23%
Respiratory
184.00M
11.49%
āļŠāļāļīāļāļīāļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļĻāļļāļāļĢāđāļāļĩāđ 20 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļĻāļļāļāļĢāđāļāļĩāđ 20 āļ.āļ.
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
The Vanguard Group, Inc.
14.11%
BlackRock Institutional Trust Company, N.A.
10.88%
State Street Investment Management (US)
3.69%
AQR Capital Management, LLC
3.29%
LSV Asset Management
2.87%
āļāļ·āđāļ āđ
65.16%
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
The Vanguard Group, Inc.
14.11%
BlackRock Institutional Trust Company, N.A.
10.88%
State Street Investment Management (US)
3.69%
AQR Capital Management, LLC
3.29%
LSV Asset Management
2.87%
āļāļ·āđāļ āđ
65.16%
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Investment Advisor
43.97%
Investment Advisor/Hedge Fund
20.04%
Hedge Fund
6.81%
Research Firm
3.26%
Pension Fund
2.56%
Bank and Trust
0.95%
Individual Investor
0.41%
Sovereign Wealth Fund
0.10%
Venture Capital
0.10%
āļāļ·āđāļ āđ
21.80%
āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļ
îāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļĪāļŦāļąāļŠāļāļĩāđ 1 āļĄ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļĪāļŦāļąāļŠāļāļĩāđ 1 āļĄ.āļ.
āļāđāļ§āļāđāļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļāļēāļ
āļāļģāļāļ§āļāļŠāļāļēāļāļąāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
2025Q4
1391
200.94M
77.29%
-50.68M
2025Q3
1485
219.88M
84.58%
-37.41M
2025Q2
1527
205.34M
78.98%
-50.49M
2025Q1
1611
213.21M
82.04%
-52.34M
2024Q4
1647
218.39M
84.67%
-40.43M
2024Q3
1625
211.80M
82.26%
-47.57M
2024Q2
1676
208.67M
81.14%
-51.47M
2024Q1
1700
205.29M
80.30%
-45.21M
2023Q4
1767
202.90M
79.38%
-24.07M
2023Q3
1835
205.61M
80.45%
-25.35M
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļīāļāļāļĢāļĢāļĄāļāļđāđāļāļ·āļāļŦāļļāđāļ
îāļāļ·āđāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
āđāļāļĨāļĩāđāļĒāļ%
āļ§āļąāļāļāļĩāđ
The Vanguard Group, Inc.
35.78M
13.76%
+3.64M
+11.31%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
27.75M
10.68%
-529.65K
-1.87%
Sep 30, 2025
State Street Investment Management (US)
9.34M
3.59%
-185.02K
-1.94%
Sep 30, 2025
AQR Capital Management, LLC
4.18M
1.61%
+921.26K
+28.30%
Sep 30, 2025
LSV Asset Management
7.83M
3.01%
-154.92K
-1.94%
Sep 30, 2025
MFS Investment Management
9.43M
3.63%
-674.26K
-6.67%
Sep 30, 2025
Geode Capital Management, L.L.C.
4.82M
1.85%
+419.78K
+9.55%
Sep 30, 2025
Private Management Group, Inc.
3.14M
1.21%
+6.13K
+0.20%
Sep 30, 2025
UBS Financial Services, Inc.
2.73M
1.05%
-3.19M
-53.87%
Sep 30, 2025
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ETF āļāļĩāđāđāļāļĩāđāļĒāļ§āļāđāļāļ
îāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 2 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 2 āļ.āļ.
āļāļ·āđāļ
āļŠāļąāļāļŠāđāļ§āļ
State Street SPDR S&P Pharmaceuticals ETF
1.72%
Alger Russell Innovation ETF
1.39%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.22%
First Trust Health Care Alphadex Fund
1.1%
Invesco S&P SmallCap Health Care ETF
1.07%
Brandes US Small-Mid Cap Value ETF
1.05%
iShares U.S. Pharmaceuticals ETF
0.65%
Lattice Hartford Multifactor Small Cap ETF
0.5%
WisdomTree U.S. SmallCap Dividend Fund
0.5%
Royce Quant Small-Cap Quality Value ETF
0.45%
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
State Street SPDR S&P Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ1.72%
Alger Russell Innovation ETF
āļŠāļąāļāļŠāđāļ§āļ1.39%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
āļŠāļąāļāļŠāđāļ§āļ1.22%
First Trust Health Care Alphadex Fund
āļŠāļąāļāļŠāđāļ§āļ1.1%
Invesco S&P SmallCap Health Care ETF
āļŠāļąāļāļŠāđāļ§āļ1.07%
Brandes US Small-Mid Cap Value ETF
āļŠāļąāļāļŠāđāļ§āļ1.05%
iShares U.S. Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ0.65%
Lattice Hartford Multifactor Small Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.5%
WisdomTree U.S. SmallCap Dividend Fund
āļŠāļąāļāļŠāđāļ§āļ0.5%
Royce Quant Small-Cap Quality Value ETF
āļŠāļąāļāļŠāđāļ§āļ0.45%
āđāļāļīāļāļāļąāļāļāļĨ
îāļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
1.03B
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
āļ§āļąāļāļāļĩāđ
āđāļāļīāļāļāļąāļāļāļĨ
āļ§āļąāļāļāļĩāđāļāļąāļāļāļķāļ
āļ§āļąāļāļāļĩāđāļāļģāļĢāļ°āđāļāļīāļ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
Feb 12, 2026
OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Mar 12, 2026 going ex on Feb 23, 2026
Feb 23, 2026
Mar 12, 2026
Feb 23, 2026
Nov 10, 2025
OGN.NB Final Cash Dividend of gross USD 0.02 paid on Dec 11, 2025 going ex on Nov 20, 2025
Nov 20, 2025
Dec 11, 2025
Nov 20, 2025
Aug 05, 2025
OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Sep 11, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Sep 11, 2025
Aug 15, 2025
May 01, 2025
OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Jun 12, 2025 going ex on May 12, 2025
May 12, 2025
Jun 12, 2025
May 12, 2025
Feb 13, 2025
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 13, 2025 going ex on Feb 24, 2025
Feb 24, 2025
Mar 13, 2025
Feb 24, 2025
Oct 31, 2024
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 12, 2024 going ex on Nov 12, 2024
Nov 12, 2024
Dec 12, 2024
Nov 12, 2024
Aug 06, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 12, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 12, 2024
Aug 16, 2024
May 02, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Jun 13, 2024 going ex on May 10, 2024
May 13, 2024
Jun 13, 2024
May 10, 2024
Feb 15, 2024
OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 14, 2024 going ex on Feb 23, 2024
Feb 26, 2024
Mar 14, 2024
Feb 23, 2024
Nov 02, 2023
OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 14, 2023 going ex on Nov 10, 2023
Nov 13, 2023
Dec 14, 2023
Nov 10, 2023
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļēāļĢāđāļāđāļāļŦāļļāđāļ
îāļ§āļąāļāļāļĩāđ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļ§āļąāļāļāļĩāđ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
